Related Experiment Video
Updated: Mar 9, 2026
04:07
Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
Published on: February 24, 2023
2.3K
Summary
The FDA approved rucaparib, a PARP inhibitor, for advanced ovarian cancer patients with BRCA mutations. This approval targets women who have undergone prior chemotherapy, marking a significant advancement in targeted cancer therapy.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Advanced ovarian cancer often presents challenges in treatment, particularly after multiple chemotherapy regimens.
- BRCA1 and BRCA2 gene mutations are key drivers in a subset of ovarian cancers, influencing therapeutic strategies.
Purpose of the Study:
- To announce the U.S. Food and Drug Administration (FDA) approval of a new therapeutic agent for a specific patient population.
- To highlight the importance of companion diagnostics in personalized medicine.
Main Methods:
- The FDA reviewed clinical data on the efficacy and safety of rucaparib.
- The FoundationFocus CDxBRCA test was evaluated for its ability to accurately detect BRCA alterations.
Main Results:
- Rucaparib (PARP inhibitor) received FDA approval for treating advanced ovarian cancer.
- The FoundationFocus CDxBRCA test was approved as a companion diagnostic for identifying eligible patients.
Conclusions:
- The approval of rucaparib offers a new targeted treatment option for women with advanced ovarian cancer and BRCA mutations.
- Companion diagnostics are crucial for ensuring appropriate patient selection for targeted therapies like rucaparib.
Related Concept Videos
02:56Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
10.0K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
10.0K
02:49Cancer Therapies
10.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.5K
02:34Inhibition of Cdk Activity
6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K